Editorial
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 24, 2020; 11(12): 990-995
Published online Dec 24, 2020. doi: 10.5306/wjco.v11.i12.990
New standard in locally advanced rectal cancer
Sebastián Solé, Ramón Baeza, Carolina Gabler, Felipe Couñago
Sebastián Solé, Ramón Baeza, Carolina Gabler, Department of Radiation Oncology, IRAM Clinic, Santiago 7630294, Chile
Sebastián Solé, Ramón Baeza, Carolina Gabler, Radiation Oncology Program Universidad Diego Portales, Santiago 7630294, Chile
Felipe Couñago, Department of Radiation Oncology, Hospital Universitario Quirónsalud Madrid, Madrid 28223, Spain
Felipe Couñago, Clinical Department, Faculty of Biomedicine, Universidad Europea, Madrid 28028, Spain
Author contributions: All authors contributed equally to designing and performing this research, and all authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sebastián Solé, MD, Director, Department of Radiation Oncology, IRAM Clinic, Santiago 7630294, Chile. sebasole@gmail.com
Received: July 31, 2020
Peer-review started: July 31, 2020
First decision: September 17, 2020
Revised: October 1, 2020
Accepted: October 20, 2020
Article in press: October 20, 2020
Published online: December 24, 2020
Processing time: 139 Days and 19.6 Hours
Core Tip

Core Tip: In this review we intend to ascertain the optimal neoadjuvant therapy in patients with locally advanced rectal cancer. In terms of chemotherapy (CT) it has recently been demonstrated that oxaliplatin-based CT after short-course radiotherapy results in greater pathological response and lower acute toxicity than concomitant chemoradiotherapy. Studies presented during 2020 have also shown this benefit, as well as better disease and metastasis-free survival. Our review suggests that probably total neoadjuvant treatment should be the new standard treatment for these patients. However, we will have to wait for the full text publications of these studies to confirm this statement.